Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 19 studies | 44% ± 15% | |
lung | 18 studies | 49% ± 18% | |
peripheral blood | 17 studies | 38% ± 12% | |
intestine | 13 studies | 46% ± 21% | |
eye | 10 studies | 61% ± 22% | |
kidney | 9 studies | 60% ± 14% | |
liver | 7 studies | 49% ± 16% | |
bone marrow | 6 studies | 32% ± 13% | |
pancreas | 5 studies | 69% ± 27% | |
placenta | 5 studies | 49% ± 31% | |
lymph node | 5 studies | 57% ± 18% | |
uterus | 4 studies | 67% ± 12% | |
prostate | 4 studies | 47% ± 11% | |
breast | 4 studies | 60% ± 9% | |
adipose | 3 studies | 22% ± 9% | |
adrenal gland | 3 studies | 48% ± 7% | |
esophagus | 3 studies | 58% ± 26% | |
skin | 3 studies | 43% ± 20% | |
thymus | 3 studies | 66% ± 21% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 127416.69 | 258 / 258 | 100% | 2197.79 | 230 / 230 |
brain | 100% | 46116.79 | 2642 / 2642 | 100% | 1420.02 | 705 / 705 |
kidney | 100% | 40217.28 | 89 / 89 | 100% | 1134.45 | 901 / 901 |
thymus | 100% | 43716.23 | 653 / 653 | 100% | 2156.03 | 605 / 605 |
liver | 100% | 54645.55 | 226 / 226 | 100% | 2148.35 | 405 / 406 |
skin | 100% | 13117.70 | 1803 / 1809 | 100% | 771.63 | 472 / 472 |
ovary | 100% | 19026.06 | 180 / 180 | 100% | 492.98 | 428 / 430 |
prostate | 100% | 17257.35 | 244 / 245 | 100% | 1156.85 | 501 / 502 |
breast | 100% | 15161.36 | 459 / 459 | 99% | 848.64 | 1107 / 1118 |
pancreas | 100% | 11380.48 | 328 / 328 | 99% | 558.58 | 176 / 178 |
uterus | 100% | 13991.81 | 170 / 170 | 99% | 591.88 | 453 / 459 |
bladder | 100% | 15018.24 | 21 / 21 | 98% | 801.16 | 496 / 504 |
intestine | 100% | 15293.34 | 965 / 966 | 97% | 557.23 | 511 / 527 |
stomach | 99% | 11929.26 | 356 / 359 | 98% | 482.01 | 279 / 286 |
lung | 98% | 12110.37 | 564 / 578 | 96% | 454.28 | 1111 / 1155 |
esophagus | 100% | 15582.27 | 1443 / 1445 | 79% | 255.83 | 145 / 183 |
eye | 0% | 0 | 0 / 0 | 100% | 1276.41 | 80 / 80 |
tonsil | 0% | 0 | 0 / 0 | 100% | 419.86 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 1196.39 | 1 / 1 |
muscle | 100% | 17822.33 | 801 / 803 | 0% | 0 | 0 / 0 |
adipose | 100% | 14943.19 | 1201 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 17206.52 | 1330 / 1335 | 0% | 0 | 0 / 0 |
spleen | 97% | 8112.76 | 234 / 241 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 586.23 | 28 / 29 |
heart | 95% | 19111.14 | 818 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 21% | 2699.77 | 196 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0043409 | Biological process | negative regulation of MAPK cascade |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005829 | Cellular component | cytosol |
GO_0005634 | Cellular component | nucleus |
GO_0019899 | Molecular function | enzyme binding |
GO_0004867 | Molecular function | serine-type endopeptidase inhibitor activity |
GO_0008429 | Molecular function | phosphatidylethanolamine binding |
GO_0019901 | Molecular function | protein kinase binding |
GO_0005515 | Molecular function | protein binding |
GO_0005524 | Molecular function | ATP binding |
GO_0003723 | Molecular function | RNA binding |
Gene name | PEBP1 |
Protein name | Phosphatidylethanolamine-binding protein 1 (PEBP-1) (HCNPpp) (Neuropolypeptide h3) (Prostatic-binding protein) (Raf kinase inhibitor protein) (RKIP) [Cleaved into: Hippocampal cholinergic neurostimulating peptide (HCNP)] |
Synonyms | PEBP PBP |
Description | FUNCTION: Binds ATP, opioids and phosphatidylethanolamine. Has lower affinity for phosphatidylinositol and phosphatidylcholine. Serine protease inhibitor which inhibits thrombin, neuropsin and chymotrypsin but not trypsin, tissue type plasminogen activator and elastase (By similarity). Inhibits the kinase activity of RAF1 by inhibiting its activation and by dissociating the RAF1/MEK complex and acting as a competitive inhibitor of MEK phosphorylation. .; FUNCTION: HCNP may be involved in the function of the presynaptic cholinergic neurons of the central nervous system. HCNP increases the production of choline acetyltransferase but not acetylcholinesterase. Seems to be mediated by a specific receptor (By similarity). . |
Accessions | ENST00000261313.3 P30086 |